Willow Biosciences added to NYSE-listed Cannabis ETF

Willow Biosciences Inc (TSE:WLLW) (OTCQX:CANSF) (FRA:3D7) said it has been added to The Cannabis ETF (NYSE:THCX), an exchange-traded fund listed on the NYSE Arca, which tracks the Innovation Labs Cannabis Index, a portfolio of 33 stocks that are expected to benefit from the growth of the legal global marijuana, cannabidiol (CBD) and hemp industries. 

The cannabinoid producer said inclusion in the index is part of THCX’s expansion to include various cannabis industry sub-themes, which will now include Willow’s manufacturing capabilities. 

READ: Willow Biosciences CEO Trevor Peters discusses how biosynthetically produced cannabinoids could shake up the cannabis industry

“As the only publicly traded, pure-play company that is biosynthetically producing cannabinoids, inclusion in THCX will allow us to reach a much broader group of investors looking to capture the large, global, total addressable market Willow is targeting,” Willow president and chief executive Trevor Peters said in a statement.

“As we have just commenced the commercialization stage of our first cannabinoid, cannabigerol (CBG), this milestone comes at the perfect time as we are transitioning into a revenue-generating company,” he added.

Contact the author at [email protected]

Follow him on Twitter @Cal_Proac

Story by ProactiveInvestors